Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02035384 · ClinicalTrials.gov registry record
Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 69
- Enrollment target
NCT02035384: Completed study, sponsored by Novo Nordisk A/S.
NCT02035384 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 69 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02035384 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 69 participants
- Enrollment target
Study Summary
This study is conducted in Europe, and North and South America. The aim of this study is to provide additional documentation of the immunogenicity, and obtain additional clinical data, of turoctocog alfa in the setting of normal clinical practise in patients previously treated with a factor VIII agent (FVIII).
Interventions
- DRUG turoctocog alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2014-06-05 |
| Est. Completion | 2020-01-15 |
What the finished NCT02035384 record still lists
NCT02035384 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 69 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which turoctocog alfa is the first listed.
NCT02035384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02035384 about?
NCT02035384 is a clinical study titled "Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A". This study is conducted in Europe, and North and South America. The aim of this study is to provide additional documentation of the immunogenicity, and obtain additional clinical data, of turoctocog alfa in the setting of normal clinical practise in patients previously treated with a factor VIII age...
What is the current status of trial NCT02035384?
This trial is currently completed. The enrollment target is 69 participants. The study started on 2014-06-05. Estimated completion is 2020-01-15.
What interventions are being tested in trial NCT02035384?
The interventions under investigation include: turoctocog alfa (DRUG).
Who is sponsoring clinical trial NCT02035384?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI